Astellas Gains Hearing Disorder Therapy from Frequency Therapeutics
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 7 (Table of Contents)
Published: 30 Jul-2019
DOI: 10.3833/pdr.v2019.i7.2442 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Astellas Pharma has licensed the ex-US rights to FX-322 from Frequency Therapeutics for the treatment of sensorineural hearing loss for a total potential deal value of US$625 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS